drugset

drugset / Trial / NCT04062019

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

NCT04062019 ↗

Phase 2 Unknown 15 enrolled Peking University People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on idiopathic inflammatory myopathy (IIM).

Timeline

Start: 2019-08-30
Primary completion: 2021-03-31
Completion: 2021-06-30

Publications

Background Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977 Jul;56(4):255-86. doi: 10.1097/00005792-197707000-00001. No abstract available.
Miao M, Li Y, Huang B, Chen J, Jin Y, Shao M, Zhang X, Sun X, He J, Li Z. Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study. Rheumatol Ther. 2021 Jun;8(2):835-847. doi: 10.1007/s40744-021-00301-3. Epub 2021 Apr 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	aldesleukin	Protein / enzyme biologic	1e+06 iu	Subcutaneous

Indications